Product Name :
Linifanib (ABT-869)
CAS No.:
796967-16-3
Purity :
> 97%
Shipping:
Shipped on dry ice.
Storage :
Powder: -20 °C, 3 years; 4 °C, 2 yearsIn solvent: -80 °C, 6 months; -20 °C, 1 month
SMILES:
CC1=CC(=C(F)C=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=N[NH]C4=CC=C3)N
Product Description :
Linifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent cancer cells (i.{{138605-00-2} site|{138605-00-2} Biological Activity|{138605-00-2} References|{138605-00-2} supplier} e.{{548-04-9} site|{548-04-9} Biological Activity|{548-04-9} References|{548-04-9} supplier} FLT3). Phase 3.
Formula:
C21H18FN5O
Molecular Weight :
375.41
Synonyms:
AL39324,RG3635
Additional Information:
|CAS No. 796967-16-3 ; |Synonyms AL39324,RG3635 ; |Formula C21H18FN5O ; |Molecular Weight 375.41 ; |SMILES CC1=CC(=C(F)C=C1)NC(=O)NC2=CC=C(C=C2)C3=C4C(=N[NH]C4=CC=C3)N ; |Product Description Linifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent cancer cells (i.PMID:28006892 e. FLT3). Phase 3. ; |Purity > 97% ; |Shipping Shipped on dry ice. ; |Storage Powder: -20 °C, 3 years; 4 °C, 2 yearsIn solvent: -80 °C, 6 months; -20 °C, 1 month ; |Solubility Overview Soluble in DMSO